Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by severe itch, significantly affecting patients’ quality of life. Increased understanding of the underlying pathomechanism has led to the development of effective new systemic treatments, including biologics and Janus kinase inhibitors. However, responses to these new treatments vary among patients, highlighting the need for personalized approaches. This article provides an overview of AD’s epidemiology, pathogenesis, and management strategies, focusing on the effectiveness and safety of new systemic treatments and patient-centered dosing regimens. It also explores future biomarker predictions and discusses new systemic treatments currently in development.